AGIOS PHARMACEUTICALS, INC. Deferred Tax Assets, Deferred Income
AGIOS PHARMACEUTICALS, INC. (AGIO) had Deferred Tax Assets, Deferred Income of $0 as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2021-02-25
- 2020-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2019-12-31: Deferred Tax Assets, Deferred Income $14.37M.
- 2018-12-31: Deferred Tax Assets, Deferred Income $21.96M.
- 2017-12-31: Deferred Tax Assets, Deferred Income $41.24M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $14.37M 10-K · filed 2021-02-25 |
| 2018-12-31 | $21.96M 10-K · filed 2020-02-19 |
| 2017-12-31 | $41.24M 10-K · filed 2019-02-14 |
| 2016-12-31 | $8.05M 10-K · filed 2018-02-14 |
| 2015-12-31 | $7.05M 10-K · filed 2017-02-16 |
| 2014-12-31 | $8.71M 10-K · filed 2016-02-26 |
| 2013-12-31 | $23.17M 10-K · filed 2015-02-24 |
| 2012-12-31 | $33.25M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |